G protein gene variants in schizophrenia by Gokce, Hatice Humeyra Yavuz et al.
Original article
Address for correspondence: Bedia Cakmakoglu. Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Molecular Medicine, Capa, Istanbul, Turkey. 
Telephone: +90 212 4142000-33305. Fax: +90 212 5324171. E-mail: bedia@istanbul.edu.tr
G protein gene variants in schizophrenia










1 Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
2 Department of Medical Biology, Faculty of Medicine, Istanbul University, Istanbul, Turkey.
3 Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.
4 Department of Biochemistry, Faculty of Pharmacy, Istanbul Yeni Yuzyil University, Istanbul, Turkey.
Received: 03/05/2019 – Accepted: 11/04/2019
DOI: 10.1590/0101-60830000000227
Abstract
Background: Various studies demonstrating enhanced vulnerability to apoptosis may contribute to the pathobiology of schizophrenia. Objective: Thus, G 
proteins may provide an intriguing link between the signal transduction, and apoptotic hypotheses of schizophrenia. In the light of these findings, we investigated 
whether G protein gene polymorphisms (GNAS1-T393C and GNB3-C825T) accounted for an increased risk of schizophrenia. Methods: The present analyses 
were based on 100 subjects diagnosed with schizophrenia, and on 100 unrelated healthy controls. The genotyping of GNAS1-T393C, and GNB3-C825T gene 
polymorphisms were performed using the polymerase chain reaction- restriction fragment length polymorphism (PCR-RFLP). Results: We demonstrated the 
positive association of GNB3-C825T gene variants with schizophrenia risk (p: 0.023). In our study, more prevalent CC genotype frequencies were detected in 
GNB3 in patients compared with the frequencies in the controls. The individuals with GNB3-C825T CC genotype had 2 fold increased risk for schizophrenia 
(p: 0.011, c2: 6.39, OR:2.14, 95% CI: 1.18-3.90). Discussion: Our study results suggested that GNB3-C825T polymorphism might be associated with schizophrenia.
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Introduction
Schizophrenia is a common psychiatric illness that is characterized 
by psychotic phenomena such as delusions, hallucinations, and 
thought disorder, along with impairment in emotions and social 
function1. The lifetime morbidity risk is approximately 1% in 
schizophrenia2. Schizophrenia is a complex biological disorder whose 
pathogenesis is likely to be governed by a number of different risk 
factors. It is well-established that the heritability of schizophrenia 
was over 80%1,2. Family, twin, and adoption studies over the past 
century strongly indicated that predisposition is largely genetically 
determined. Several environmental risk factors such as perinatal 
viral infections, obstetric trauma, and maternal malnutrition have 
been identified as risk factors for schizophrenia3. The prevalence of 
schizophrenia is similar among men, and women4. However, the 
course of schizophrenia is often more severe in men with earlier 
onset of the disease5. The diagnosis relies on clinical observation 
and self-reports because there is no available diagnostic laboratory 
tests for schizophrenia. 
Heterotrimeric guanine nucleotide binding proteins (G proteins) 
play key roles in the conversion of external receptor signals into 
intracellular response. G proteins are composed of a, b, and g 
subunits, and each subunit is coded by various different genes6. Many 
studies showed that the dysregulation of neurotransmitters signal 
transduction pathways7, and enhanced vulnerability to apoptosis 
may both contribute to the pathobiology of the schizophrenia8. 
Thus, G proteins may provide an intriguing link between the signal 
transduction, and apoptotic hypotheses of schizophrenia. In an animal 
study, a G protein signaling gene knockout or mutant mice has been 
reported to develop abnormal involuntary movements9. In addition, 
G-protein measurements were suggested to be a biochemical marker 
for schizophrenia10.
The synonymous T393C polymorphism in the GNAS1 gene was 
reported to be possibly significantly affect Gas mRNA expression, 
with TT genotypes displaying highest Gas expression and greater 
apoptotic vulnerability in several different cell types11. The GNB3 
gene codes the b-subunit 3 of G-proteins, and (GNB3) C825T 
polymorphism (T-allele) results in increased intracellular signal 
transduction in G-protein coupled receptors12. The T-allele results 
in an in-frame deletion of 41 amino acids, and has been associated 
with major depression13. Moreover, the C/T or T/T genotype has 
been reported to be associated with seasonal affective disorder14. 
The aim of the present study was to investigate the possible 
associat ion between GNB3-C825T and GNAS1-T393C 
polymorphisms with the presence of schizophrenia.
Material and methods
Subject selection
The study sample comprised of 100 patients with schizophrenia, and 
100 healthy controls with no personal or family history of psychiatric 
disorders. All patients had psychotic or active symptoms at the time 
of the study. Most patients were receiving antipsychotic medication 
at the time of scan. Each patient was given a diagnostic assessment 
based on the clinical interviews using a Structured Clinical Interview 
for Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV)15. The mean age was 41.25 ± 10.98 years for 
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schizophrenia patients, and 40.54 ± 12.83 years for controls. No 
significant difference was detected between the study, and control 
groups in terms of mean age and sex distribution.
To minimize the effect of ethnic differences in gene frequencies, 
the study participants were selected among the Turkish population 
living in the western region of Turkey. The study was approved by 
the Medical Ethics Committee of Istanbul Medical Faculty, and all 
participants (i.e. controls, patients or unaffected family members (on 
behalf of some patients) gave written informed consents.
Measurements, protocol and procedure
All subjects were examined in accordance with a standardized 
interview, and examination. Assessment was done using a form which 
required patient information regarding demographic and personal 
details of the patients and informants, symptoms of the patients, 
history of present illness, details of medical or surgical interventions, 
past history, family history, personal history, premorbid personality, 
details of physical examination, mental status examination, and the 
diagnostic formulation. The diagnosis was made using a Structured 
Clinical Interview for DSM-IV (SCID-I)16. The patients were then 
screened on various rating scales like Brief Psychiatric Rating 
Scale17,18 for patients with schizophrenia, Scale for the Assessment of 
Positive Symptoms (SAPS)19 and Scale for the Assessment of Negative 
Symptoms (SANS)19 for patients with schizophrenia. The subtypes 
of schizophrenia patients were classified in accordance with the 
DSM-IV. Relatives and controls with schizophrenia were excluded 
from the study using the Structured Clinical Interview for DSM-IV16. 
Healthy and unrelated volunteers with no psychiatric disorders 
were selected as the control group. Control group and first-degree 
relatives of schizophrenia patients were screened using the Schedule 
for Affective Disorders and Schizophrenia-Lifetime Version20,21. 
Inclusion and exclusion criteria
The patients diagnosed with schizophrenia in accordance with 
the DSM-IV were included in the study. Patients diagnosed with 
psyhiatric disorders other than schizophrenia were excluded from 
the study. Patients with a history of neurological or medical disorder 
that might affect neuropsychological function (seizures, head trauma, 
stroke, brain tumor, meningitis, etc.) or with a recent history of 
alcohol abuse or psychoactive drugs were also excluded from the 
study. In addition, control subjects control subjects with the diagnosis 
of any physical or psychiatric health problems were excluded from 
the study. Control subjects had no history of physical health problem.
Polymorphism analysis
DNA was extracted from white blood cells using the method 
of Miller et al.22. GNB3-C825T, and GNAS1-T393C geno-
types were determined using the PCR-RFLP method. We 
used for the GNB3-C825T polymorphism, sense primer 
5’- TGACCCACTTGCCACCCGTGC -3’ and antisense primer 
5’- GCAGCAGCCAGGGCTGGC -3’; for the GNAS1-T393C poly-
morphism, sense primer 5’- CTCCTAACTGACATGGTGCAA-3’and 
antisense primer 5’- TAAGGCCACACAAGTCGGGGT -3’ (Invi-
trogen, Carlsbad, CA, USA). The PCR mixture contained 100 ng 
DNA template, 0.5 μM of each primer, 1.5 mM MgCl
2
, 2 mM dNTPs 
(Invitrogen) and 1 U Taq DNA polymerase (Intron Bio, Sungnam, 
Kyungki-Do, Korea). After denaturing the DNA for 5 min at 94 °C, 
the reaction mixture was subjected to 35 cycles of denaturing for 1 
min at 94 °C, 45 s annealing at 60 °C and 1 min extension at 72°C 
for the GNB3-C825T. The 268-bp PCR product was digested with 
BseDI restriction endonuclease and the digested products were 
separated by electrophoresis on a 3% agarose gel (UltraPure Agarose; 
Invitrogen, Carlsbad, CA) and visualized using ethidium bromide. 
The C/C genotype contains a unique restriction site that results in 
152- and 116-bp products, and the T/T genotype is not cut (268-bp), 
allowing the GNB3-C825T genotype to be determined. For the 
GNAS1-T393C polymorphism, the reaction mixture was subjected 
to 35 cycles of denaturing for 30 s at 94 °C, 45 s annealing at 58 °C 
and 1 min extension at 72 °C. The PCR product (345 bp) was digested 
with BseGI and the digested products were separated and identified 
as above. Allele T contained no BseGI site whereas C contained the 
BseGI site, giving rise to 259- and 86-bp products. Each gel was read 
by two observers unaware of the subject’s status. The reactions were 
repeated for avoiding any possible conflicts.
Statistical analysis
Statistical analyses were performed using the Statistical Package for 
the Social Sciences (SPSS) software package (revision 11.5 SPSS Inc., 
Chicago, IL, U.S.A.). Data were expressed as mean ± SD. Differences 
in the distribution of genotypes or alleles of DNA repair gene between 
cases and controls were tested using the Chi-square statistic. Linkage 
disequilibrium among DNA repair gene polymorphisms was assessed 
using D’ and r2 values obtained through the haploview program 
(http://www.broad.mit.edu/mpg/haploview/documentation.php). 
P value < 0.05 was considered statistically significant.
Results
Control subjects, and patients were adjusted for age, and sex. Table 1 
shows the characteristics of the patients and control groups. The 
number of smokers was higher in the patient group compared with 
the numbers in the control group (P: 0.003), and the number of 
alcohol consumers was higher among the control group compared 
with number in the patient group (P < 0.001).
There were statistically significant differences in GNB3-C825T 
genotypes between the controls, and patients (c2: 7.52; p: 0.023). 
However, there were no significant differences for GNB3-C825T 
allele frequencies between the schizophrenia patients, and controls 
(p > 0.05) (Table 2).
Frequencies of GNB3-C825T T+ genotype were higher among 
the controls compared with the frequencies in patients which 
demonstrating a protective role of T+ genotype against schizophrenia 
(p: 0.011, c2: 6.39, OR: 0.466, 95% CI: 0.25-0.84).
Frequencies of GNB3-C825T CC genotype in patients were 
higher compared with the frequencies in the controls. The individuals 
having GNB3-C825T CC genotype had 2 fold increased risk for 
schizophrenia (p: 0.011, c2: 6.39, OR: 2.14, 95% CI: 1.18-3.90).
Individuals carrying GNB3-C825T TC genotype had decreased 
risk for schizophrenia (p: 0.011, c2: 6.48, OR: 0.483, 95% CI: 0.27-
0.84). Frequencies of TC genotype in controls were higher than the 
frequencies in patients.
However, we found no significant differences for GNAS1-T393C 
genotype and allele frequencies between schizophrenia patients, and 
controls (p > 0.05) (Table 2).
While GNB3-C825T CC genotype was associated with 
schizophrenia in univariate analysis, GNB3-C825T CC genotype was 
also associated with this disease in multivariate logistic regression 
analysis by adjusting sex, and age (Table 3).
Table 1. Characteristics of the schizophrenia patients and control groups
Controls Patients P X2 OR 95% CI
Age 40.54 ± 12.83 41.25 ± 10.98 0.675 – – –
Sex (male/female) 49/51 48/52 0.887 0.02 1.04 0.59-1.82
Smoking (%, yes/no) 44.0/56.0 65.0/35.0 0.003 8.89 2.36 1.33-4.17
Alcohol (%, yes/no) 18.0/82.0 1.0/99.0 0.000 16.8 0.046 0.006-0.35
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Table 2. The distribution of GNAS1-T393C and GNB3-C825T genotype frequencies in the patient and control groups




TT 40 (40%) 38 (38%)
CC 13 (13%) 12 (12%)
TC 47 (47%) 50 (50%)
ALLELES
T 127 (63.5%) 126 (63%)
C 73 (36.5%) 74 (37%)
GNB3- C825T GENOTYPES
TT 16 (16%) 17 (17%)
CC 26 (26%) 43 (43%)
TC 58 (58%) 40 (40%)
ALLELES
T 90 (45%) 74 (37%)
C 110 (55%) 126 (63%)
Discussion
Imbalances of regulatory apoptotic proteins have associations 
with various diseases in addition to their association with cancer. 
Some researchers have reported a link between apoptosis and 
schizophrenia, which was based on the changes of some apoptotic 
protein levels in different brain areas of schizophrenic patients23. Due 
to this regulation, G-protein and its subunits become a question for 
schizophrenia by its transductional mechanisms and its critical role 
for the regulation of programmed cell death24. These findings logically 
might point out a link between G-proteins, and schizophrenia. 
Therefore, we hypothesized that the genes encoding for G-protein 
subunits might have a relation and be nominated as a candidate for 
schizophrenia.
In our research, our findings have showed the positive association 
of GNB3 gene variants as a risk factor for schizophrenia. In addition, 
the frequency of CC genotype in GNB3 was more prevalent 
in patients in contrast to controls. Moreover, we found that the 
frequencies of T+ and TC genotype of GNB3 gene were common 
in controls than the frequencies in patients. Researchers showed in 
a previous study that GNB3-C825T polymorphism was associated 
with treatment response in various antipsychotic drugs that support 
the aim of our study about the relation G protein and schizophrenia 
especially for the people receiving pharmacological treatment25. TT 
genotype or T allele carriers of C825T polymorphism were found to 
be associated with treatment response to serotonin selective reuptake 
inhibitors (SSRI) in the treatment of depression25. Supporting these 
data, we have found that T+ and TC genotype might have a protective 
role in schizophrenia with our patient scale. This results need to be 
improved and supported with further analyses by studying with 
larger scale.
Researchers reported that increased efficacy of GNAS1 signaling 
is observed in striatum and mononuclear leukocytes in schizophrenia 
patients26. In addition, the T393C polymorphism in GNAS1 was 
shown to be genetically linked to deficit schizophrenia in an Italian 
population sample, such that the 393TT genotype was observed 
significantly more in these patients (37.1%) than the controls 
(22.8%)27. Supporting this, the 393TT genotype appears to increase 
GNAS mRNA expression, as measured in bladder tumors and 
Table 3. The results of multivariate logistic regression analysis
Variables in the Equation B S.E. Wald Sig. Exp (B) 95% CI for EXP(B)
Lower Upper
Age 0.007 0.012 0.322 0.571 1.007 0.983 1.031
Sex -0.056 0.290 0.037 0.847 0.946 0.535 1.671
GNB3-C825T CC -0.773 0.305 6.405 0.011 0.462 0.254 0.840
Variable(s) entered on step 1: Age, sex, GNB3-C825T CC genotype.
adipose tissue of patients suffering from transitional cell carcinoma28. 
On the other hand, we found no significant differences for GNAS1-
T393C genotype and allele frequencies between schizophrenia 
patients, and controls14. We suggested that G-protein subunit Gαs 
(also known as GNAS1) may be one of the molecules for contributing 
to the pathophysiology of schizophrenia.
In conclusion, our findings suggested that GNB3-C825T 
polymorphism might be associated with schizophrenia and with its 
underlying mechanism. To understand the main impact and capacity 
for schizophrenia, further studies with larger sample groups are 
required to clarify the role of G protein genes for schizophrenia.
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